Kurt Losert 
We are excited to announce the publication of a landmark paper in Nature Medicine highlighting a major advance in targeted immunotherapy for fibrolamellar carcinoma (FLC). The article, A Therapeutic Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma: A Phase 1 Trial, describes a collaborative effort by researchers at the Johns Hopkins University School of Medicine (Baltimore, MD) …
Today, on World Cancer Research Day, we join the global cancer community in recognizing the power of research to transform lives. This year’s theme, “Cancer Research Needs Us All,” resonates with our mission at the Fibrolamellar Cancer Foundation (FCF)—where patients, families, researchers, and supporters unite to accelerate progress against fibrolamellar carcinoma (FLC), a rare and …
As summer heats up, so does FCF’s commitment to fibrolamellar research. We’ve launched our 2025 Summer Appeal and invite you to join our effort to develop more effective treatments for fibrolamellar patients. The Fibrolamellar Cancer Foundation (FCF) is now supporting four groundbreaking clinical trials, an extraordinary milestone for our rare disease community. One of these trials has …
Registration is now open for the Patient & Family Gathering to be held on September 12 – 14, 2025, at the Lake Mansfield Trout Club in Stowe, Vermont. This unique event brings together patients, families and caregivers dealing with fibrolamellar, helping them build connections and friendships with others facing similar challenges. Please click here to …
From June 9–11, 2025, a gathering of prominent cancer researchers took place in Greenwich, Connecticut. The event focused on exchanging research findings, fostering collaboration, and strategizing advancements in the treatment of fibrolamellar carcinoma (FLC). This marked the sixth international summit of key FLC researchers hosted by the Fibrolamellar Cancer Foundation (FCF). The summit’s opening keynote …
On June 9 – 11, 2025, FCF hosted its sixth Fibrolamellar Scientific Summit. The goal of this meeting was to bring together the fibrolamellar research community to share knowledge and to collaborate in the search for a cure. The opening session of the conference featured a panel discussion highlighting the latest advancements in targeted immunotherapy …
FCF is pleased to announce that it has awarded a grant to Aleksander Skardal, PhD, of Ohio State University to develop new models of fibrolamellar carcinoma (FLC). A major challenge to researching FLC is the scarcity of lab models that accurately mimic how this cancer behaves in the human body. To address this, the team …
The FCF is pleased to announce the funding of a study led by Dr. Sean Ronnekleiv-Kelly of the University of Wisconsin-Madison. This research will explore a key protein, SLC16A14, that is involved in the growth and survival of fibrolamellar cancer (FLC) cells using a new mouse model that the team has developed. Evidence suggests that …
A new clinical trial for fibrolamellar patients is now enrolling patients! This phase 1/2 study, Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma, will test the safety, side effects and best dose of DT2216 in combination with the chemotherapy agent, irinotecan. …